145 – Case Study: Digital Innovation Accelerating R&D (S10E10)

Welcome to the deep dive. Today, we're diving
straight into a really dynamic area. how digital
innovation is supercharging the, well, the traditionally
lengthy process of pharmaceutical research and
development. Yeah, it really is speeding things
up. We've gathered some fascinating material,
and our goal today is to explore a compelling
case study that vividly illustrates this acceleration,
you know, from the initial spark of identifying
a potential drug, all the way through to making
it efficiently. Right. And we'll hit on the benefits,
but also, you know, the challenges researchers
run into. It's all based on actual scientific
finding. Exactly. And for you, the learner, our
aim is to give you a clear, insightful understanding
of this fast -moving field, hopefully sparking
some aha moments without getting too overwhelming.
Precisely. We're moving beyond just theory here.
We're looking at real examples of how these digital
tools are actually being used to speed up and
refine every stage of the drug discovery pipeline.
It's a genuinely transformative shift. Okay,
let's jump right into those initial stages then.
Early discovery. A cornerstone here is high throughput
screening, HTS. For you, the learner, can you
maybe break down what that technique involves?
Sure. So high throughput screening, HTS, is basically
a way to rapidly test huge numbers of chemical
compounds. Think libraries with hundreds of thousands,
even millions of molecules. Wow, that's a lot.
It is. And you test them to see if any interact
with a specific biological target, something
relevant to a disease. It's like casting this
incredibly wide net to see what sticks. The goal
is finding those initial hit molecules that show
some promising activity. OK. And we often hear
the term drugability. What does that tell us
about a target? Ah, drugability. Yeah, that's
a key concept. It's essentially an assessment
of how likely it is we'll find a drug -like molecule
that can effectively bind to and modulate a specific
biological target. So some targets are just easier
than others? Exactly. Some are just inherently
easier to design drugs for because their structure
or how they work. It's kind of like saying some
puzzles are just simpler to solve. It depends
on what a molecule needs to do to bind effectively
and also, you know, our past successes with similar
targets. That makes sense. So once these initial
hits pop up from HTS, how do researchers start
narrowing things down to boost the chances of
finding a real drug? I've seen references to
drug likeness rules. Right, that's where those
rules come in. A really well -known one is the
rule of five. It's basically a set of practical
guidelines that came from looking at lots of
existing successful drugs. OK. These rules look
at simple molecular properties, things like molecular
weight, how fat soluble the molecule is, the
number of hydrogen bond donors and acceptors,
stuff like that. And what do those properties
tell you? Well, by checking those, we can predict
if a compound is likely to have good oral bioavailability.
Meaning, can you take it as a pill and will it
get absorbed properly into your bloodstream?
Got it. So these rules act like an initial filter.
They help us prioritize compounds from those
huge screening libraries, focusing on the ones
with a better shot at becoming effective oral
drugs. The scale and speed enabled by digital
tech, including analyzing these properties, have
really changed the game here. So it's like a
digital sieve for the most promising leads. Precisely.
And while these rules are super useful for compounds
we already have, it gets even more sophisticated
when we're designing totally new compounds virtually
before any lab work. You mean just on a computer?
Yeah. Computational tools let us predict these
same properties for molecules that only exist
in the model. We can bake drug likeness right
into the design process itself. So you avoid
wasting time on synthesizing duds. Exactly. Avoids
investing time and resources synthesizing stuff
that's likely to have major absorption or distribution
problems down the line. But it's not perfect,
right? The sources suggest even compounds that
break these rules can still be useful. Oh, absolutely.
Experienced medicinal chemists, pharmacologists,
they can often analyze data even from non -drug
-like compounds and get crucial structure activity
relationship information, SAR, structure activity
relationship. Basically, they figure out which
parts of the molecule are doing the work, hitting
the target, even if the whole molecule doesn't
look like a typical drug. And that knowledge
can then guide optimization, leading to new,
more drug -like molecules based on those initial
findings. So the rules are a great starting point,
but the scientist's expertise in reading the
data is still totally essential. Okay, moving
on from finding the molecule, understanding how
it behaves in the body is critical. We're talking
ADMET properties now. That's correct, ADMET.
It stands for absorption, distribution, metabolism,
excretion, and toxicity. These five are absolutely
critical. Why so critical? Well, a molecule might
look amazing in a lab dish, but if it's poorly
absorbed or gets broken down too fast, or it
doesn't reach the right tissues, or crucially
causes nasty side effects, it's probably never
going to become a medicine. Right. And this seems
like another area where digital tools are making
a big difference, predicting these things earlier.
Absolutely. We now have a whole arsenal of computational
tools and what we call computational descriptors.
Yeah, think of them as ways to turn a molecule
structure and properties, its size, shape, charge,
distribution into numbers a computer can analyze.
OK. By analyzing these numbers, we can build
predictive models. How might it be absorbed?
Where might it go? How might enzymes break it
down? How is it eliminated? And importantly,
might it be toxic? So you can flag problems much
sooner. Exactly. Let's just focus efforts on
compounds more likely to succeed and stop wasting
resources on ones likely to fail because of a
bad 80 -met profile. The source is also mentioned
using in vitro systems like hepatocytes, liver
cells to study metabolism. How do those lab tests
fit in with the computer predictions? Good question.
Those in vitro systems, like using liver cells,
give us a more, well, biological look at how
the body's enzymes might break down a drug candidate.
Because they have the actual machinery. Right.
They contain the real biological machinery for
drug metabolism. So we can identify potential
breakdown products, metabolites, see how fast
the drug is metabolized. This is crucial for
predicting things like drug interactions. Where
one drug messes with another's metabolism. Exactly.
And for figuring out dosing for clinical trials.
The in vitro data then helps us refine and validate
the computational models, making the predictions
better. I also saw something about molecular
interaction fields, MIFS. What are they used
for? Ah, MIFS. They offer a more detailed way
to map how a molecule might interact with its
environment, like its target or metabolic enzymes.
Think of it like feeling the molecular landscape
around a drug using different virtual probes.
Probes? Yeah, probes representing different chemical
features, a positive charge, a hydrogen bond
donor, things like that. By mapping the energy
between the molecule and these probes in 3D space,
you get a map of its interaction potential. And
that helps compare molecules. It helps evaluate
how similar two molecules are in terms of potential
interactions. Useful for finding molecules with
similar activity or maybe cross -reactivity with
other targets or enzymes. Sounds powerful, but
the sources hinted at challenges, especially
with aligning the molecules. Why is that tricky?
That's a really important point. To compare myths
effectively, you need the molecules aligned in
a biologically relevant way. Ideally, how they
actually bind to the target. Which you might
not know. Often, you don't have that detailed
structural info, so you try aligning them based
on other things like common structures or pharmacophores,
the key bits thought to cause the activity. But
that's less certain. It introduces uncertainty,
yeah. The less info you have on the binding mode,
the harder and potentially less reliable the
alignment is. That alignment challenge can be
a real bottleneck for using MIFS effectively.
Okay, let's pivot now to a specific example of
this acceleration in action, the InForm -1 study
for hepatitis C virus. This seems like a really
telling case. It is, absolutely. InForm -1 is
a great example of how a smart strategy, using
what we knew about the virus and efficient trial
design, really sped up hep C treatment development.
What was the basic idea behind it? The rationale
was to combine two different direct -acting antivirals,
DAAs, hitting different essential viral enzymes.
It was kind of inspired by HIV treatment, where
combination therapies hitting multiple targets
worked really well against the virus and resistance.
And the two drugs in Form 1 were RG7128 and RG7227?
Exactly. They were designed to inhibit different
key proteins the Hepcivirus needs to replicate.
The thinking was, block two different things
at once, you get a much stronger antiviral punch,
and make it way harder for the virus to develop
resistance. Makes sense. What about the actual
trial design? Who took part? In Form 1 was a
phase I trial. It was randomized, double -blind,
and used to sending doses. Okay. Can you unpack
that a bit? Sure. Randomized means patients were
randomly assigned to get the drug combo or a
placebo. Double -blind means neither the patients
nor the researchers knew who got what until the
end. Ascending dose means they started with low
doses in some groups and gradually increased
the dose in later groups to check safety carefully.
And the patients? They were adults with chronic
hepatitis C, genotype 1, common type. Importantly,
it included people who'd never had treatment
and people who'd tried older interferon therapies,
even some who hadn't responded to interferon
at all. And what were the main things the researchers
were looking at? Safety was top priority, of
course. any side effects related to the treatment.
They also closely watched viral kinetics, basically,
how fast and how much the HCV RNA levels the
virus's genetic material dropped in the blood.
It's a direct measure of effectiveness. Right.
Plus, they looked for any signs of the virus
developing resistance. And they did pharmacokinetic
studies, PK, to see how the drugs were absorbed,
distributed, metabolized, excreted, and, crucially,
if the two drugs interfered with each other when
given together. You can actually see the impressive
viral load drops in the data tables from the
source material. So what were the key results?
Did it work? The results were really encouraging.
All the dose groups finished the study without
any major treatment -related safety issues. No
dose adjustments needed. Nobody had to stop because
of side effects. That's good. And the PK analysis
showed no significant interactions between the
two drugs, which is always a worry with combos.
And maybe most importantly, they saw substantial
rapid drops in HCV RNA levels across all the
groups getting the active drugs. A strong antiviral
effect. Sounds like a really positive outcome,
then. And the source material stresses this study
had a big impact on hep C treatment going forward.
Oh, absolutely. In Form 1 gave strong early clinical
proof that an all oral interferon free combo
therapy with DAAs was not just possible, but
highly effective. It was a major turning point.
Really paving the way for what came next. Exactly.
It paved the way for the rapid development of
the super effective, much better tolerated DAA
therapies we have now. These have revolutionized
HCV treatment, changing millions of lives. The
speed in Form 1 showed results. Using advanced
data analysis and efficient design, it was night
and day compared to earlier HCV research timelines.
Really showed the power of a targeted, digitally
informed approach. Shifting from hitting the
virus directly, let's talk about getting the
drug into the patient effectively. Solubility
and bioavailability, these seem like common read
blocks. They certainly are. Huge hurdles sometimes.
For a drug to work, it needs to dissolve properly
in body fluids to get absorbed into the bloodstream
and reach its target. But loads of promising
drug candidates just don't dissolve well in water.
Which limits how much actually gets into the
system. Right. It limits their bioavailability,
the fraction of the dose that actually reaches
the circulation unchanged and could do its job.
So what can researchers do? Are there formulation
tricks? Yes. There's a whole range of formulation
techniques to boost solubility. Things like adjusting
the pH, using other liquids called co -solvents
to help dissolve the drug, forming complexes
with other molecules, shrinking the particle
size that's called micronization, or making solid
dispersions where the drug is spread out in a
soluble carrier. The idea of pro drugs also came
up regarding bioavailability. How did they fit
in? Pro drugs. They're basically inactive versions
of a drug. chemically tweaked to overcome problems
like poor solubility or low bioavailability.
How's that work? Often you attach a chemical
group that makes it more water -soluble or helps
it cross biological membranes better. Once it's
administered and absorbed, the body uses enzymes
or chemistry to snip off that extra group, releasing
the active drug where it needs to be. The source
mentioned an example with phenytoin derivatives
in dogs having better bioavailability. Can you
explain that? Yeah, that's a good illustration.
Finitoin is an anti -seizure drug, but it's not
very soluble. Researchers attached these NS -loxalkyl
groups to it. Creating the prodrugs. Right. These
modified versions, the prodrugs, showed better
bioavailability in dogs, especially with food,
even if their water solubility wasn't drastically
higher. The thinking is the added group probably
helped absorption across the gut lining. maybe
by making it more fat -loving or interacting
better with transporters. And then it converts
back to phenytoin in the body. Exactly. Once
absorbed, it converts back to active phenytoin,
shows how smart chemical modification can fix
pharmacokinetic limitations. We've mostly talked
about pills, oral delivery. What about other
routes? Nanoparticles were mentioned. Nanoparticles
are a really exciting area for drug delivery.
especially for more targeted or controlled release.
They're incredibly tiny particles made of polymers
or lipids, for example. And the drug goes inside
or on them? Yeah, you can encapsulate the drug
inside or attach it to the surface. By carefully
engineering the nanoparticles' size, shape, surface
properties, you can achieve specific goals. Like
what? like protecting the drug from breaking
down, keeping it in the bloodstream longer, or
even targeting it specifically to diseased tissues
or cells. For instance, they're being looked
at for delivering drugs right to the lungs for
respiratory diseases, or trying to get drugs
across the blood -brain barrier for conditions
like Alzheimer's. So digital tools are key in
discovery. formulation, delivery. What about
the actual making of the drug? The chemical synthesis
and manufacturing. Are digital innovations important
there, too? Absolutely. Digital tools are increasingly
used to optimize chemical synthesis and manufacturing.
The goal is always robust, efficient, cost -effective,
scalable production of high -quality drugs while
minimizing waste. The sources mentioned controlling
things like nucleation and crystal growth. Why
are those tiny details so critical? Nucleation,
the first formation of crystals, and then how
they grow, these are super critical for solid
drugs. They dictate the physical properties,
particle size, shape, even the crystal form,
or polymorph. And that affects how the drug works.
Profoundly. These crystal -level details impact
solubility, stability on the shelf, how well
the powder flows during manufacturing, and ultimately
bioavailability and how well it works in the
patient. Digital tools, like modeling and simulation,
help scientists understand and control these
crystallization processes precisely. Ensuring
consistency. Right. Consistent production of
high -quality material with the right properties.
You see lots of examples in journals like Organic
Process Research and Development, OPR &D, where
computational tools optimize crystallization.
Quality control is obviously huge. The discussion
mentioned chromatography and the need for specificity,
especially for mutagenic impurities. Yes, ensuring
purity and safety is non -negotiable. Analytical
techniques like HPLC, GC, they're essential for
separating and quantifying the drug and any impurities.
And specificity means? Specificity means the
method must be able to tell the drug apart from
anything else related stuff. Breakdown products,
process impurities, mutagenic impurities are
a big worry because they can damage DNA, potentially
cause cancer, even at tiny levels. So you need
really sensitive tests. Extremely sensitive in
specific methods. Yeah, often down to parts per
million or even billion. Sometimes complex sample
prep is needed just to detect these trace amounts
accurately. What about residual metal catalysts?
I saw metal scavengers mentioned. Why are they
needed? Good point. Metal catalysts off the palladium,
platinum, things like that, are used a lot in
synthesis to make reactions happen efficiently.
But tiny traces can remain in the final drug.
And that's bad. Potentially toxic. Yeah, even
in small amounts. You have to remove them. Metal
scavengers are materials designed specifically
to grab onto these residual metals. They form
complexes you can easily filter out or remove.
So choosing the right scavenger is important.
Critical. And optimizing how you use it. Process
chemists often use systematic experiments, sometimes
guided by digital tools for experimental design
and analysis, to find the best, most cost effective
scavenger for their process. Again, OPRND has
tons of examples showing how digital tools help
optimize reactions and purification, including
metal removal. Okay, so we've gone from discovery,
formulation, manufacturing. The final critical
stage is clinical trials. How are digital tools
changing that phase? They're revolutionizing
clinical trials too, really impacting everything
from the initial design through to analyzing
the huge amounts of data generated. For example?
Well, sophisticated statistical software is key
for designing trials with the right number of
participants for reliable results. And defining
clear primary endpoints, the main outcome measure
is fundamental. Digital platforms help define,
track, and analyze these precisely. The discussion
also mentioned different trial types, like non
-inferiority trials. How do digital tools help
there? Right. Non -inferiority trials aim to
show a new treatment isn't significantly worse
than an existing standard one. They rely heavily
on stats to see if the new drugs effect falls
within a pre -set Martin. So software is crucial.
Essential for calculating sample sizes, performing
complex analyses. Plus, computational modeling
can explore different scenarios and assess the
trial's statistical power beforehand. And biomarkers,
they seem increasingly common. How are digital
tools helping with those? Biomarkers. Measurable
indicators like proteins or genes are getting
integrated everywhere. Digital tools are absolutely
vital for managing and analyzing the large complex
data sets involved. Using sophisticated stats
and machine learning to identify potential biomarkers,
understand their link to disease or drug response,
and ultimately use them to improve patient selection
for trials, getting the right drug to the right
patient, and monitoring effectiveness. Finally,
the rise of AI and expert systems in healthcare
came up. What's their potential impact? Huge
potential. AI can help optimize trial design,
predict patient dropout, personalize treatments
within trials. It can analyze unstructured data
like health records or images to find eligible
patients or insights you'd miss otherwise. Beyond
trials, too. Yeah, AI is being explored for diagnosis,
treatment recommendations, predicting outcomes.
But it's important to remember the regulations
for AI medical devices are still evolving. Careful
validation and ethics are key. It all sounds
incredibly promising, but the outline also mentioned
challenges with adopting all this digital innovation.
What are the main roadblocks? There definitely
are challenges. Data integration is a big one.
You've got massive diverse data from discovery,
preclinical manufacturing, clinical trials. Getting
it all together in a standard usable way is complex.
needs robust systems. You need robust, reliable
computational models. Their accuracy depends
on good input data and sophisticated algorithms
that requires constant development and validation.
And then there's the upfront investment in infrastructure
hardware, software, data storage. Plus, crucially,
training people to use these tools effectively.
But despite those hurdles, the overall direction
seems clear. More digital acceleration. Absolutely.
Despite the challenges, the trend is overwhelmingly
towards adopting more digital tools across the
board. The potential benefits, faster timelines,
more efficiency, lower costs, and ultimately
better, safer drugs for patients are just too
significant to ignore. Well, this has been a
really insightful deep dive into how digital
tools are fundamentally reshaping pharma R &D.
To quickly summarize for you, the learner, we've
seen how these innovations speed up initial drug
discovery, optimize preclinical studies, streamline
manufacturing, and transform clinical trials.
That HCV case study in Form 1 really highlighted
the potential for rapid progress when you combine
scientific insight with digital power. Yeah,
it's clear digital innovation isn't just some
future idea in pharma R &D. It's happening right
now, driving real advancements and promising
an even faster, more efficient pipeline ahead.
So here's a final thought to chew on. As these
digital tools get even smarter, think of more
powerful AI, more accurate predictive models,
seamless data integration. Could we see a fundamental
shift in how research is done? Could we eventually
reach a point where we can almost, you know,
predict and design new therapies with incredible
speed and accuracy, maybe even anticipate future
health threats and develop solutions proactively?
It's a fascinating, maybe even transformative
prospect. It certainly is. And for anyone wanting
to dig deeper into any of this, Definitely explore
the scientific literature. There's a wealth of
information out there in this fast -moving field.
Thanks for joining us for this deep dive. We
look forward to bringing you another fascinating
exploration next time.